Loading...
•
Dec 31, 2023
Arcutis Q4 2023 Earnings Report
Arcutis reported strong Q4 2023 financial results driven by ZORYVE® cream revenue growth and FDA approval of ZORYVE® foam.
Key Takeaways
Arcutis Biotherapeutics, Inc. reported a significant increase in total revenues for Q4 2023, driven by strong demand for ZORYVE® cream. The company also achieved FDA approval for ZORYVE® foam and anticipates a transformational year in 2024 with potential approval for roflumilast cream for atopic dermatitis.
Q4 net product revenues for ZORYVE® cream increased by 357% compared to Q4 2022, reaching $13.5 million.
Arcutis received FDA approval for ZORYVE® topical foam for seborrheic dermatitis in December 2023.
The FDA has set a PDUFA action date of July 7, 2024, for roflumilast cream for atopic dermatitis.
Arcutis' strong financial position supports investment in plaque psoriasis and seborrheic dermatitis launches and continued pipeline development.
Arcutis
Arcutis
Forward Guidance
Arcutis anticipates a transformational year in 2024 with potential approval for roflumilast cream for atopic dermatitis.
Positive Outlook
- Strong revenue growth trend reinforcing demand for new treatment options and physician adoption of ZORYVE
- Two FDA-approved products in the midst of their commercial launches
- Mid-year PDUFA action date for roflumilast cream for atopic dermatitis
- Expanding product portfolio
- Robust development pipeline